DB07107
DB07107 is a potent agent resistant T315I mutant Bcr-Abl tyrosine kinase inhibitor. DB07107 is also a potent Akt1 inhibitor with an IC50 value of 360 nM.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 552332-71-5
- Fòrmula: C23H22N4O
- Peso molecular:370.45
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
|
Akt1 360 nM (IC50) |
DB07107 is more effective in blocking drug-resistant T315I mutant than the wild-type Bcr-Abl. DB07107 (C23H22N4O) from DrugBank showed the highest binding energy with XP score of -14.045 kcal/mol[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 552332-71-5
-
Peso molecular 370.45
-
Fòrmula C23H22N4O
-
SMILES
N[C@@H](COC1=CN=CC(/C=C/C2=CC=NC=C2)=C1)CC3=CNC4=C3C=CC=C4
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
[1]. Banavath HN, et al. Identification of novel tyrosine kinase inhibitors for drug resistant T315I mutant BCR-ABL: a virtual screening and molecular dynamics simulations study. Sci Rep. 2014 Nov 10;4:6948. [Content Brief]
[2]. Li Q, et al. Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1679-85. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
DB07107 Related Classifications
HY-123390 Related Classifications
Powered by Bioz